These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives. Imbimbo BP; Lozupone M; Watling M; Panza F Expert Opin Investig Drugs; 2020 Sep; 29(9):919-933. PubMed ID: 32657175 [TBL] [Abstract][Full Text] [Related]
4. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
5. Do anti-amyloid-β drugs affect neuropsychiatric status in Alzheimer's disease patients? Panza F; Lozupone M; Bellomo A; Imbimbo BP Ageing Res Rev; 2019 Nov; 55():100948. PubMed ID: 31454563 [TBL] [Abstract][Full Text] [Related]
6. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Ono K; Tsuji M Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023927 [TBL] [Abstract][Full Text] [Related]
7. Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals. d'Oleire Uquillas F; Jacobs HIL; Hanseeuw B; Marshall GA; Properzi M; Schultz AP; LaPoint MR; Johnson KA; Sperling RA; Vannini P Neuroimage Clin; 2018; 17():388-396. PubMed ID: 29159051 [TBL] [Abstract][Full Text] [Related]
8. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of antibody-based therapies to treat Alzheimer's disease: just a matter of timing? Cedernaes J; Schiöth HB; Benedict C Exp Gerontol; 2014 Sep; 57():104-6. PubMed ID: 24835192 [TBL] [Abstract][Full Text] [Related]
14. Does HIV infection contribute to increased beta-amyloid synthesis and plaque formation leading to neurodegeneration and Alzheimer's disease? Fulop T; Witkowski JM; Larbi A; Khalil A; Herbein G; Frost EH J Neurovirol; 2019 Oct; 25(5):634-647. PubMed ID: 30868421 [TBL] [Abstract][Full Text] [Related]
15. What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials. Bullain S; Doody R J Neurochem; 2020 Sep; 155(2):120-136. PubMed ID: 32277473 [TBL] [Abstract][Full Text] [Related]
16. The past, present, and future of disease-modifying therapies for Alzheimer's disease. Suzuki K; Iwata A; Iwatsubo T Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305 [TBL] [Abstract][Full Text] [Related]
17. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S Elife; 2020 Jun; 9():. PubMed ID: 32510331 [TBL] [Abstract][Full Text] [Related]
18. Amyloid-beta immunotherapy for Alzheimer's disease. Fu HJ; Liu B; Frost JL; Lemere CA CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640 [TBL] [Abstract][Full Text] [Related]